Sign in

Rapid antigen kits key in scaling up Covid-19 testing

An antigen is a protein (in this case present on the virus) that induces an immune response in the body in the form of production of antibodies against a disease, and detecting its presence through an antigen-based test determines a present infection.

Updated on: Jul 27, 2020, 01:09:30 IST
Hindustan Times, New Delhi | By
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

With at least 400,000 tests conducted for the second day in a row till Sunday morning , India is clearly ramping up its coronavirus disease (Covid-19) testing, with the introduction of rapid antigen testing being the key behind the sudden sharp increase in testing -- from around 250,000 tests a day a month ago.

A health worker shows a coronavirus (COVID-19) rapid antigen test kit during a testing drive at the Community Center in Sector-9 A, Gurugram. (Parveen Kumar/Hindustan Times)
A health worker shows a coronavirus (COVID-19) rapid antigen test kit during a testing drive at the Community Center in Sector-9 A, Gurugram. (Parveen Kumar/Hindustan Times)

Nearly one in four Covid-19 tests for diagnosing the viral disease conducted currently uses a rapid antigen test kit.

An antigen is a protein (in this case present on the virus) that induces an immune response in the body in the form of production of antibodies against a disease, and detecting its presence through an antigen-based test determines a present infection.

According to the Union health ministry data released on Sunday, 4,42,263 tests were done in the previous 24 hours across roughly 1300 approved laboratories across the country.

Of this, nearly one lakh samples were tested using rapid antigen based testing kits to diagnose Covid-19. The rest were the fold standard reverse transcription polymerase chain reaction (RT-PCR) tests.

India aims to increase its testing capacity to one million tests per day on average in coming weeks.

“Antigen testing has also played its role in ramping up Covid-19 testing as it’s quicker, easier to perform and cheaper than RT-PCR,” said Harsh Vardhan, Union health minister.

India has conducted almost 10.6 million tests since January 22.

The antigen based kit largely being used currently, especially by governments, is Indian Council of Medical Research approved ‘Standard Q COVID-19 Ag detection kit’ developed by SD Biosensor, a South Korea based company that has its manufacturing unit in Manesar, Gurugram.

Delhi was the first state to start antigen based Covid-19 testing last month, and other states that have deployed antigen testing in a significant way include Maharashtra, Gujarat, Karnataka, Telangana, Uttar Pradesh, Punjab and some north Eastern states.

Experts say it is a good tool to perform mass testing.

“Since positives results are confirmed positives, it will work in picking up cases, even if it is not able to pick up all cases. In areas where the viral load is very high it should work well, and that’s what we want -- that cases are tracked early. RT-PCR is a better test but can’t be deployed on mass scale as it’s not only cumbersome and expensive but also takes much longer. It’s ok to conduct confirmatory negative tests through RT-PCR,” said Dr Amita Jain, head, microbiology department, King George’s Medical University, Lucknow.

According to health ministry, lower rate of Covid-19 deaths can also be attributed to aggressive testing along with improved hospital infrastructure by combining public and private sector efforts that enabled early identification of Covid-19 patients.

India’s case fatality rate as on Sunday was 2.31%. Patients are also recovering in large numbers on a daily basis, and Saturday’s government data showed highest recoveries in a single day of 36,145 Covid-19 patients. The total number of recoveries has reached 8,85,576, with the current recovery rate of 63.92%.

“Most positive cases do not require hospitalization, and those needing intensive care is actually a minuscule number. Most people who are in hospital have got moderate disease with good chances of recovery. The need is to take care of our old and vulnerable population, especially those with co-morbidities, who are at high risk of developing severe illness,” says Dr Rommel Tickoo, senior consultant, department of internal medicine, Max Healthcare.

...

  • Rhythma Kaul
    ABOUT THE AUTHOR
    Rhythma Kaul

    Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More